Insights

Strategic fundraising Saol has secured up to 115 million in milestone-based capital from Oaktree Capital Group to support SL1009 launch preparation. This indicates strong investor confidence and potential for accelerated commercialization activities in multiple regions, presenting opportunities to align BD efforts with near-term launch milestones and capital deployment timelines.

Global clinical footprint Operations across the US, Ireland, and Bermuda combined with Phase II and Phase III trials for SL1009 suggest multi-region regulatory and market access considerations. This creates avenues to engage regional CROs, payer strategists, and regional distributors to support trials, regulatory filings, and eventual market access strategies.

NDA resubmission momentum The FDA NDA resubmission for SL1009 indicates ongoing regulatory activity and a potential near-term path to approval. This presents sales potential post-approval in rare metabolic disorders, with opportunities to discuss commercial readiness, manufacturing scalability, and orphan disease specialty distribution partnerships.

Rare disease focus Saol targets pyruvate dehydrogenase complex deficiency and other CNS-related orphan indications. This positioning makes them a candidate for specialty pharma partnerships, contract manufacturing for niche therapies, and collaborations with patient advocacy groups to support market education and patient identification strategies.

Data and diagnostics synergy Existing collaborations and genotype testing rights with Medosome Biotec and GeneDx indicate emphasis on precision diagnostics to identify eligible patients. This provides a sales angle to offer integrated diagnostic and therapeutic solutions, leveraging genomic screening to streamline patient recruitment for trials and eventual treatment adoption in specialty channels.

Similar companies to Saol Therapeutics

Saol Therapeutics Tech Stack

Saol Therapeutics uses 8 technology products and services including Amazon Web Services, WordPress, CookieYes, and more. Explore Saol Therapeutics's tech stack below.

Media & News

Saol Therapeutics's Email Address Formats

Saol Therapeutics uses at least 4 email formats:
Saol Therapeutics Email FormatsExamplePercentage
FLast@saolrx.comJDoe@saolrx.com
77%
Last@saolrx.comDoe@saolrx.com
11%
First@saolrx.comJohn@saolrx.com
8%
FirstLast@saolrx.comJohnDoe@saolrx.com
4%

Frequently Asked Questions

What is Saol Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Saol Therapeutics's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Saol Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Saol Therapeutics's official website is saolrx.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Saol Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, Saol Therapeutics's annual revenue is estimated to be $25M - $50M.

What is Saol Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Saol Therapeutics's SIC code is 2834 - Pharmaceutical Preparations and NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Saol Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, Saol Therapeutics has approximately 34 employees across 3 continents, including North America, Europe and Asia. Key team members include Chief Operating Officer: P. H., Vice President Of Research & Development: L. O. and Vice President Of Quality: M. R. Explore Saol Therapeutics's employee directory with LeadIQ.

What industry does Saol Therapeutics belong to?

Minus sign iconPlus sign icon
Saol Therapeutics operates in the Pharmaceutical Manufacturing industry.

What technology does Saol Therapeutics use?

Minus sign iconPlus sign icon
Saol Therapeutics's tech stack includes Amazon Web Services, WordPress, CookieYes, Shopify, Microsoft 365, New Relic, Vimeo and DigitalOcean Web Hosting.

What is Saol Therapeutics's email format?

Minus sign iconPlus sign icon
Saol Therapeutics's email format typically follows the pattern of FLast@saolrx.com. Find more Saol Therapeutics email formats with LeadIQ.

How much funding has Saol Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, Saol Therapeutics has raised $17M in funding. The last funding round occurred on Aug 05, 2019 for $17M.

When was Saol Therapeutics founded?

Minus sign iconPlus sign icon
Saol Therapeutics was founded in 2015.
Saol Therapeutics logo

Saol Therapeutics

Pharmaceutical ManufacturingGeorgia, United States11-50 Employees

Saol Therapeutics is a privately held, clinical-stage pharmaceutical company focused on developing treatments for central nervous system disorders, including pain management and spasticity, as well as orphan diseases. Its work centers on advancing candidates through clinical trials, with multiple studies active in the United States at the present time. The company aims to expand therapeutic options for patients and clinicians treating these populations, supported by collaborations and research activities pursued across its operations in the United States, Ireland, and Bermuda.
Headquartered in Roswell, Georgia, Saol Therapeutics operates within the pharmaceutical manufacturing sector and maintains a global footprint through its offices in Roswell, Dublin, and Hamilton. Its activities have included partnerships and strategic initiatives to identify and enroll patients for rare disease trials, underscoring a focus on identifying underserved patient populations and advancing novel interventions through late-stage development. A notable recent development includes progression in a Phase III trial for a PDCD-related therapy and ongoing Phase II trials, reflecting continued clinical-stage advancement." } API 0.1 0.7 0.3 0.4 0.2 0.5 0.6 0.1 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 } 0.72 0.85 0.15 0.70 0.40 0.10 0.60 0.30 0.50 0.20 0.90 0.25 0.35 0.45 0.55 0.65 0.75 0.80 0.95 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95 0.05 0.15 0.25 0.35 0.45 0.55 0.65 0.75 0.85 0.95

Section iconCompany Overview

Phone number
Website
saolrx.com
SIC Code
2834 - Pharmaceutical Preparations
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2015
Employees
11-50

Section iconFunding & Financials

  • $17M

    Saol Therapeutics has raised a total of $17M of funding over 1 rounds. Their latest funding round was raised on Aug 05, 2019 in the amount of $17M as a Venture Round.

  • $25M - $50M

    Saol Therapeutics's revenue is estimated to be in the range of $25M - $50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.